Corgenix Announces Diagnostic Development Agreement with Lilly
-- Companies to focus on potential companion diagnostic opportunity --
DENVER -- May 22, 2013
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer
of diagnostic test kits, announced today that it has entered into a
collaboration agreement with Eli Lilly and Company (NYSE:LLY) to develop
diagnostic technology in support of a Lilly oncology pipeline program. Under
the terms of the agreement, the two companies will collaborate to further
advance this proprietary diagnostic technology originally developed by Lilly.
The financial terms of the agreement were not disclosed.
“We are very pleased to enter into this new and exciting collaboration with
Lilly,” said Douglass Simpson, President and CEO of Corgenix, “This
relationship strengthens our company’s program of strategic alliances in key
areas of laboratory and research medicine. The Lilly collaboration in
particular opens a new door for Corgenix as we continue to explore this
technology in global clinical research as potential new technology to meet the
needs of oncology clinicians worldwide.”
The collaboration with Lilly is part of Corgenix’ recently announced expansion
of its Contract Services Business Unit for contract product development,
technology application and manufacturing for the healthcare and biotechnology
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases and bone and joint
disorders, including the world’s only non-blood-based test for aspirin effect.
Corgenix diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over 50
diagnostic products through a global distribution network and has significant
experience in product submissions to the FDA and other worldwide regulatory
authorities. Additionally Corgenix contract develops and manufactures products
for key medical and life science companies in state-of-the-art facilities in
Colorado. The company operates under a Quality Management System that is ISO
13485:2012 certified and compliant with FDA regulations. More information is
available at www.corgenix.com (Corporate website) and www.corgenix.net
(Contract Services website).
Corgenix Medical Corp.
Corgenix Company Contact:
William Critchfield, 303-453-8903
Senior VP Operations and Finance and CFO
Armada Medical Marketing
Dan Snyders, 303-623-1190 x 230
Vice President, Public Relations Supervisor
Press spacebar to pause and continue. Press esc to stop.